Log In
Print
BCIQ
Print
Print this Print this
 

Azimilide

  Manage Alerts
Collapse Summary General Information
Company Blue Ash Therapeutics LLC
DescriptionPotassium channel blocker, class III antiarrythmic
Molecular Target Potassium channel
Mechanism of ActionK channel blocker
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationArrhythmia
Indication DetailsTreat atrial arrhythmia in post-myocardial infarction (MI) patients
Regulatory Designation

Partner

Actavis plc


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today